GENITOURINARY CANCER
Clinical trials for GENITOURINARY CANCER explained in plain language.
Never miss a new study
Get alerted when new GENITOURINARY CANCER trials appear
Sign up with your email to follow new studies for GENITOURINARY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Guided cancer drug trial aims to match right patients to right treatment
Disease control Recruiting nowThis study tests the drug atezolizumab in about 200 adults with different incurable solid tumors. Researchers use each person's tumor DNA and RNA to see if their cancer might respond to the drug. Participants receive the same dose every 3 weeks, and the study checks if the geneti…
Matched conditions: GENITOURINARY CANCER
Phase: PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
New drug combo aims to boost immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination helps the immune system fight cancer better. About…
Matched conditions: GENITOURINARY CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New hope for chemo brain: drug may shield memory during cancer treatment
Symptom relief Recruiting nowThis study tests whether the drug riluzole can prevent memory and thinking problems (often called 'chemo brain') in people receiving chemotherapy for various cancers. About 24 adults with breast, lung, or other cancers will receive either riluzole or a placebo during their chemo.…
Matched conditions: GENITOURINARY CANCER
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated May 16, 2026 22:31 UTC
-
7,000 cancer patients join quest to sniff out hidden tumor DNA
Knowledge-focused Recruiting nowThis study enrolls 7,000 people with various cancers who have had or will have treatment aimed at curing their disease. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA that might remain after treatment. The goal is to lea…
Matched conditions: GENITOURINARY CANCER
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated May 16, 2026 22:32 UTC
-
Massive study tracks rare urinary cancers to unlock treatment secrets
Knowledge-focused Recruiting nowThis study follows 1,100 adults with common and rare urinary tract cancers (like bladder, kidney, or testicular cancer) over their lifetime. Researchers collect medical records, blood, urine, and tumor samples to understand how these cancers behave and respond to treatments. The …
Matched conditions: GENITOURINARY CANCER
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 07, 2026 18:42 UTC
-
Simple blood test could spot cancer recurrence months earlier
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning sooner than standard scans. Researchers will follow 100 people with various solid tumors to see if early detection leads to better treatment options. The goal is to improve how w…
Matched conditions: GENITOURINARY CANCER
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated May 06, 2026 16:13 UTC
-
Cancer surgery opioid use under the microscope: new study tracks pills and disposal
Knowledge-focused Recruiting nowThis study looks at how many opioid pain pills people actually take after surgery for bladder, kidney, or prostate cancer. About 684 adults will report their opioid use for 30 days after leaving the hospital. The study also tests whether a simple pamphlet helps people safely disp…
Matched conditions: GENITOURINARY CANCER
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Apr 22, 2026 16:00 UTC